Operating income decreased 34.2%
Operating income changed -34.2% from the comparable as-filed period. This reverses 3 consecutive comparable moves in the opposite direction.
Ranked by interpretable importance, issuer history, magnitude, and accounting profile. No directional recommendation.
Operating income changed -34.2% from the comparable as-filed period. This reverses 3 consecutive comparable moves in the opposite direction.
Operating margin changed -28992 basis points from the comparable as-filed period. This reverses 2 consecutive comparable moves in the opposite direction.
Gross margin changed -7957 basis points from the comparable as-filed period. This reverses 2 consecutive comparable moves in the opposite direction.
Selling, general & administrative changed +34.1% from the comparable as-filed period. This reverses 3 consecutive comparable moves in the opposite direction.
Capex / revenue changed +439 basis points from the comparable as-filed period. This reverses 3 consecutive comparable moves in the opposite direction.
Inventory changed +16.5% from the comparable as-filed period. The change ranks at the 75th percentile of 4 prior comparable changes. This reverses 4 consecutive comparable moves in the opposite direction.
Shares outstanding changed -28.9% from the comparable as-filed period. The change ranks at the 12th percentile of 8 prior comparable changes. This reverses 3 consecutive comparable moves in the opposite direction.
Revenue changed -37.2% from the comparable as-filed period.
Research & development changed +229.6% from the comparable as-filed period.
Current ratio changed +47.2% from the comparable as-filed period. The change ranks at the 75th percentile of 4 prior comparable changes.
Working capital / assets changed +2094 basis points from the comparable as-filed period. The change ranks at the 75th percentile of 4 prior comparable changes.
Current liabilities changed -39.7% from the comparable as-filed period. The change ranks at the 50th percentile of 4 prior comparable changes.
Inventory / revenue changed +49394 basis points from the comparable as-filed period. This reverses 2 consecutive comparable moves in the opposite direction.
Stock-based compensation changed -100.0% from the comparable as-filed period.
Capital expenditure changed +911.6% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes. Relative percentage is de-emphasized because the comparison has a sign change.
SBC / revenue changed -686 basis points from the comparable as-filed period.
Operating cash-flow margin changed -57231 basis points from the comparable as-filed period. This reverses 3 consecutive comparable moves in the opposite direction.
R&D / revenue changed +9334 basis points from the comparable as-filed period. This reverses 3 consecutive comparable moves in the opposite direction.
Free-cash-flow margin changed -57670 basis points from the comparable as-filed period. This reverses 3 consecutive comparable moves in the opposite direction.
Method Importance combines metric-family relevance, magnitude, issuer-history unusualness, persistence, and financial-statement significance. It is analytical prioritization, not a legal materiality conclusion or investment signal.